Type 2 diabetes (T2DM) is a public health problem and the second leading cause of death in Mexico. More than 20 years after the human genome project was completed, the development of innovative technologies and methodologies to determine the genetic risk factors that predispose an individual to develop this and other pathologies, have made the implementation of genomic medicine as part of clinical practice become a reality. Although in Mexico genomic studies are still in the beginning, these have generated knowledge about the etiopathogenesis of T2DM. In this review, we will address genomic knowledge applications in clinical practice, as well as the advances in the genomics of T2DM in Mexico.
No takes yet. Share an insight, caveat, or question.
Garcia‐Ortíz et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: